CAMBRIDGE, Mass., June 13 /PRNewswire-FirstCall/ -- ViaCell, Inc. (Nasdaq: VIAC - News) announced today the signing of a cardiac collaboration agreement with the Stem Cell Internal Venture (SCIV) of Centocor Research and Development, Inc. to evaluate ViaCell’s proprietary cord blood-derived multi-potent stem cells as a potential treatment for cardiac disease in preclinical testing. The collaboration is also supported by the Biologics Delivery Systems Group of Cordis Corporation and will focus on dosing, delivery and targeting of ViaCell’s expanded proprietary cord blood stem cells using Cordis’ NOGA delivery system. Centocor and Cordis are both Johnson & Johnson companies.
